KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Abacavir; Dideoxynucleosides; Fosamprenavir; Lamivudine; Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• HIV infected subjects that are naive to anti-HIV therapy.

• History of a positive HIV test.

• At least 1000 copies/mL of HIV in their blood as screening.

Exclusion Criteria:

• Active HIV-related diseases.

• Taking other investigational drugs.

• Pregnant or breastfeeding females.

• Not be suitable to participate per investigator opinion.